T.Rowe Price Associates logo

T.Rowe Price Associates

Crunchbase
Pitchbook
Crunchbase

Deals on record

21

Common Fundraising Type

Series C

Clear Labs logo
Clear Labs

Next-generation sequencing

Wing Venture Capital logo
T. Rowe Price Associates logo
Redmile Group logo
Nimble Ventures logo
Menlo Ventures logo
Khosla Ventures logo
HBM Genomics logo
GV logo

Clear Labs develops next-generation sequencing platforms that integrate DNA sequencing, robotics, and cloud-based bioinformatics for diagnostics.

Series D
$30M
01/13/2025
Article
Saluda Medical logo
Saluda Medical

Medical device

Wellington Management logo
TPG Life Sciences Innovation logo
T. Rowe Price Associates logo
Redmile Group logo
Piper Heartland Healthcare Capital logo
Fidelity Management & Research Company logo
Action Potential Venture Capital logo

Saluda Medical develops and commercializes the Evoke® System, a closed-loop spinal cord stimulation device for managing chronic pain.

Equity
$100M
01/10/2025
Article
KoBold Metals logo
KoBold Metals

AI-powered

T Rowe Price logo
WCM Investment Management logo
StepStone logo
Standard Investments logo
Mitsubishi logo
July Fund logo
Equinor logo
Durable Capital Partners logo

Kobold Metals uses AI to identify and develop critical mineral deposits essential for the energy transition.

Series C
$537M
01/02/2025
Article
SandboxAQ logo
SandboxAQ

Quantum computing

T. Rowe Price Associates logo
US Innovative Technology Fund logo
S32 logo
Rizvi Traverse logo
PQV logo
Mumtalakat logo
IQT logo
Fred Alger Management logo

SandboxAQ develops quantum physics-based software for applications in life sciences, materials science, navigation, encryption, and cybersecurity.

Equity
$300M
12/18/2024
Article
nChroma Bio logo
nChroma Bio

Epigenetic editing

Wilson Sonsini Goodrich & Rosati logo
Wellington Management logo
T. Rowe Price logo
Sofinnova Partners logo
Sixth Street logo
Omega Funds logo
Mubadala Capital logo
Menlo Ventures logo

nChroma Bio develops innovative genetic medicines using epigenetic editing and non-viral delivery technologies to treat chronic hepatitis B and D.

Equity
$75M
12/11/2024
Article
Metsera logo
Metsera

Biopharmaceutical

Venrock logo
Wellington Management logo
T. Rowe Price logo
SymBiosis logo
SoftBank logo
Newpath Partners logo
Janus Henderson logo
GV logo

Metsera is a clinical-stage biopharmaceutical company developing next-generation treatments for obesity and metabolic diseases using their innovative platforms and Nutrient-Stimulated Hormone analog peptides.

Series B
$215M
11/13/2024
Article
Waymo logo
Waymo

Autonomous vehicles

T. Rowe Price logo
Tiger Global logo
Silver Lake logo
Perry Creek logo
Fidelity logo
Andreesen Horowitz logo
Alphabet logo

Waymo develops and operates autonomous vehicle technology, focusing on expanding its robotaxi ride-hailing services.

Series C
$5.6B
10/25/2024
Article
Seaport Therapeutics logo
Seaport Therapeutics

Neuropsychiatric

General Atlantic logo
T. Rowe Price Associates logo
Sofinnova Investments logo
Third Rock Ventures logo
PureTech Health logo
Invus logo
Goldman Sachs Alternatives logo
Foresite Capital logo

Seaport Therapeutics develops neuropsychiatric medicines using its Glyph technology platform to enhance oral bioavailability and reduce side effects, with a focus on treating depression, anxiety, and other disorders.

Series B
$225M
10/22/2024
Article
Lightmatter logo
Lightmatter

Photonic Chip Technology

T. Rowe Price Associates logo
GV logo
Fidelity Management and Research Company logo

Lightmatter is a company that develops photonic chip technology to enhance AI and high-performance computing with a focus on reducing power consumption and increasing performance.

Series D
$400M
10/16/2024
Article
Aktis Oncology logo
Aktis Oncology

Biotechnology

RA Capital Management logo
RTW Investments logo
Janus Henderson Investors logo
T. Rowe Price Associates logo
MRL Ventures Fund logo
Eli Lilly and Company logo
Bristol Myers Squibb logo
Avidity Partners logo

Aktis Oncology is a clinical-stage biotechnology company developing a proprietary radiopharmaceutical pipeline, including Nectin-4-targeted miniprotein radioconjugates, for cancer treatment.

Series B
$175M
09/30/2024
Article
ArsenalBio logo
ArsenalBio

Programmable cell therapy

Westlake Village BioPartners logo
T. Rowe Price Associates logo
SoftBank logo
Rock Springs Capital logo
Regeneron Ventures logo
Parker Institute for Cancer Immunotherapy logo
NVentures logo
Milky Way Investments Group logo

Arsenal Biosciences, Inc. is a clinical-stage company developing programmable T cell therapies for solid tumor cancers using a computationally driven approach.

Series C
$325M
09/04/2024
Article

Odyssey Therapeutics is a biotech firm specializing in developing precision immunomodulators and oncology medicines, with plans to advance multiple therapeutic programs into clinical studies.

Series C
$101M
12/05/2023
Article
RefleXion Medical logo
RefleXion Medical

Therapeutic Oncology

Venrock logo
TPG logo
T.Rowe Price Associates logo
Square Point Capital logo
Pictet logo
Pfizer Ventures logo
Johnson & Johnson Innovation logo
Hillenbrand logo

RefleXion Medical develops and commercializes SCINTIX therapy, a novel treatment for all stages of indicated solid tumor cancers, including metastatic disease, delivered via the RefleXion X1 platform.

Equity
$105M
11/15/2023
Article
Apiture logo
Apiture

Digital Banking Solutions

T. Rowe Price Investment Management logo

Apiture provides digital banking solutions, including the Apiture Digital Banking Platform, with an API-first approach and flexible solutions for over 300 banks and credit unions in the U.S.

Equity
$10M
11/14/2023
Article
Stash logo
Stash

Fintech

T. Rowe Price logo
Union Square Ventures logo
Goodwater Capital logo

Stash is a fintech company that offers an investing app, aiming to provide an affordable way for lower and middle-income consumers to invest, and has raised $40 million through a convertible note to reach profitability and plans to go public in the near future.

Debt
$40M
10/13/2023
Article
Avalyn Pharma logo
Avalyn Pharma

Biopharmaceutical

Perceptive Xontogeny Venture Funds logo
Wellington Management logo
Vida Ventures logo
T. Rowe Price Associates logo
SR One logo
Rock Springs Capital logo
RiverVest Venture Partners logo
Pivotal bioVenture Partners logo

Avalyn Pharma is a biopharmaceutical company that develops inhalation therapies for rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases, with a focus on creating new inhaled formulations of approved medicines.

Series C
$175M
09/27/2023
Article
Databricks logo
Databricks

Data and AI

Tiger Global logo
T. Rowe Price logo
Nvidia logo
Morgan Stanley logo
Franklin Templeton logo
Fidelity logo
Capital One Ventures logo
Andreessen Horowitz logo

Databricks is a data and AI company that provides a platform utilized by over 10,000 organizations globally, including more than half of the Fortune 500 companies, and has completed a Series I funding round to accelerate AI technology development and expand its team.

Series I
$500M
09/14/2023
Article
Generate:Biomedicines logo
Generate:Biomedicines

Biotherapeutics

Generate:Biomedicines is a clinical-stage biotherapeutics company that uses a machine-learning-powered generative biology platform to develop new drugs across oncology, immunology, and infectious disease.

Series C
$273M
09/14/2023
Article
Sortera Technologies logo
Sortera Technologies

Material Recycling

T. Rowe Price Associates logo
RA Capital Management-Planetary Health logo
Mitsubishi logo
Macquarie logo
Chrysalix logo
Breakthrough Energy Ventures logo
Assembly Ventures logo

Sortera Technologies is a material sorting company that uses artificial intelligence data analytics to sort pre-production aluminum and end-of-life mixed metals, enabling the use of recycled material in manufacturing, reducing costs and pollution, and increasing availability for domestic manufacturers.

Series C
$30.5M
08/31/2023
Article
Redwood Materials logo
Redwood Materials

Battery Recycling

T. Rowe Price Associates logo
OMERS logo
Microsoft logo
Goldman Sachs Asset Management logo
Deepwater Asset Management logo
Capricorn logo

Redwood Materials is a startup that specializes in recycling batteries, with a goal to recycle 300-500 GWh of batteries annually by 2030 or 2035.

Series D
$1B
08/29/2023
Article

Rapport Therapeutics is a clinical-stage biotechnology company that develops precision neuromedicines for seizure and psychiatric disorders by targeting specific neuroanatomical regions, aiming to provide better alternatives to current treatments by reducing unwanted drug-target interactions.

Series B
$150M
08/23/2023
Article